FEMY - Femsys stock jumps 21% after FDA green lights FemBloc testing
2023-06-26 12:31:58 ET
Femasys ( NASDAQ: FEMY ) shares jumped 21% midday Monday following news that the US Food and Drug Administration has approved its investigational device exemption application to begin clinical trials for its birth control product FemBloc.
The product is intended to provide women with a permanent birth control solution that does not require anesthesia, incisions or permanent implants. A pivotal study for the product is expected to begin in Q3.
More on Femsys:
- Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada, stock rises 10%
- Femasys stock dips on $3.9M equity offering
For further details see:
Femsys stock jumps 21% after FDA green lights FemBloc testing